moderate to severe plaque psoriasis

临床试验

计划入组 209 人 · 首次发布于 2024 年 8 月 7 日

已完成

NCT00791765

Moderate to Severe Plaque Psoriasis With Scalp Involvement

计划入组 124 人 · 首次发布于 2008 年 11 月 17 日

已完成

NCT07712705

HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

计划入组 515 人 · 首次发布于 2026 年 7 月 17 日

药物

查看全部 2317 →

Biotech

Approved

Brodalumab(Siliq, Kyntheum)

相关疾病：Severe Plaque psoriasis, Moderate Plaque psoriasis

Rx

Biotech

Approved

Guselkumab(Tremfya)

生产企业：Janssen Biotech, Inc., Johnson & Johnson

相关疾病：Severe Plaque psoriasis, Moderate Plaque psoriasis，另有 1 项

Rx

Biotech

Approved

Ixekizumab(Taltz)

生产企业：Eli Lilly and Company

相关疾病：Moderate to Severe Plaque Psoriasis, Active Ankylosing spondylitis，另有 2 项

Rx

机构

查看全部 657 →

PSORIASIS TREATMENT CENTER OF SOUTH FLORIDA

United States

RIGHT TO CARE

South Africa

Power to Decide

United States

资讯

查看全部 40768 →

去年

Bimzelx Shows Remarkable Five-Year Efficacy in Moderate-to-Severe Plaque Psoriasis

9个月前

Takeda's Zasocitinib Achieves Phase 3 Success in Moderate to Severe Plaque Psoriasis

前天

临床试验

Treatment of Moderate to Severe Plaque Psoriasis

Moderate to Severe Plaque Psoriasis With Scalp Involvement

HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

药物

Brodalumab(Siliq, Kyntheum)

Guselkumab(Tremfya)

Ixekizumab(Taltz)

机构

PSORIASIS TREATMENT CENTER OF SOUTH FLORIDA

RIGHT TO CARE

Power to Decide

资讯

Bimzelx Shows Remarkable Five-Year Efficacy in Moderate-to-Severe Plaque Psoriasis

Takeda's Zasocitinib Achieves Phase 3 Success in Moderate to Severe Plaque Psoriasis

FDA Accepts Takeda's Zasocitinib NDA Under Priority Review for Moderate-to-Severe Plaque Psoriasis